Reduction in the weight, gained due to dolutegravir, following switch to bictegravir

HIV-infected individuals can live with the virus for decades, and the physicians have to review the long-term health implications of weight gain as they would for any other patient. Although the integrase strand transfer inhibitors (INSTIs) class of drugs are one of the most popular regimens used for rapid reduction and maintenance in HIV cases, the weight gain resulting from their use is concerning. The use of dolutegravir (DTG) an INSTI is observed to have a weight gain in people living with HIV. Since bictegravir is also an INSTI, it is expected to show a similar weight gain.

This retrospective analyses the change in the weight in 22 patients, who showed a trend of increase in weight when on DTG and later when switched to bictegravir therapy showed reduction in the increased weight.

This is a retrospective analysis from our clinic (Dr. Saple's Clinic) in Mumbai from the duration of March 2018 to March 2021. Excessive weight gain was observed when the patients were on DTG therapy. The therapy was then switched to an equally potent integrase strand inhibitor bictegravir to get the benefit of efficacy of antiretroviral therapy and avoid the weight gain effect seen with DTG.

In our case review, we found results contrary to this. After 22 patients were treated on DTG for 9 to 24 months (mean 20.68 months), the baseline weight of 74.04 kg increased significantly to 84.26 kg (P < 0.05). After switching over to bictegravir for a mean period of 8 - 12 months (mean 11.72 months), this weight reduced to mean of 77.08 kg, a drop was clinically observed but was not statistically significant.

Our finding could be the first instance were weight loss has been reported post switching the patients from DTG therapy to Bictegravir. Considering smaller patient population this outcome may need further confirmed through large group study.